Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Paraneoplastic rheumatic syndromes].

Margarita Pileckyte1, Rūta Baliūnaite, Valerija Tamulaitiene

  • 1Clinic of Rheumatology, Kaunas University of Medicine, Lithuania. pmargarita@one.lt

Medicina (Kaunas, Lithuania)
|June 10, 2003
PubMed
Summary

Paraneoplastic syndromes, affecting 15% of cancer patients, are more common in men. Differentiating rare paraneoplastic rheumatic syndromes from primary rheumatic diseases is crucial for accurate diagnosis and treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products.

Clinical and experimental rheumatology·2023
Same author

The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.

Clinical and experimental rheumatology·2022
Same author

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

Arthritis research & therapy·2018
Same author

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.

Arthritis & rheumatology (Hoboken, N.J.)·2018
Same author

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2017
Same author

Clinical characteristics and long-term outcomes of 35 patients with Wegener's granulomatosis followed up at two rheumatology centers in Lithuania.

Medicina (Kaunas, Lithuania)·2010

Area of Science:

  • Rheumatology
  • Oncology
  • Internal Medicine

Background:

  • Paraneoplastic syndromes affect 15% of patients with malignancy, encompassing endocrine, hematological, rheumatic, and neuromuscular types.
  • These syndromes are more prevalent in males compared to females.
  • Rheumatic paraneoplastic syndromes are notably infrequent.

Purpose of the Study:

  • To review the distinctions in clinical presentation, disease progression, and outcomes between primary rheumatic diseases and paraneoplastic rheumatic syndromes.
  • To emphasize the importance of differentiating paraneoplastic syndromes from genuine rheumatic conditions.
  • To outline methods for distinguishing between these two entities.

Main Methods:

  • Literature review comparing primary rheumatic diseases and paraneoplastic rheumatic syndromes.
  • Analysis of clinical features, disease course, and patient outcomes.
  • Discussion of diagnostic differentiation strategies.

Main Results:

  • Paraneoplastic rheumatic syndromes present unique clinical characteristics, disease trajectories, and outcomes compared to primary rheumatic diseases.
  • Effective differentiation between paraneoplastic syndromes and primary rheumatic disease is essential for appropriate patient management.
  • General consensus suggests extensive occult malignancy screening is not routinely advised for most rheumatic syndromes without specific indicators.

Conclusions:

  • Accurate differentiation between paraneoplastic rheumatic syndromes and primary rheumatic diseases is critical.
  • Specific clinical findings suggestive of malignancy are necessary to warrant extensive cancer screening in patients with rheumatic syndromes.
  • Further research may clarify optimal diagnostic pathways for suspected paraneoplastic rheumatic conditions.

Related Experiment Videos